A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors

Chimeric antigen receptor (CAR) T cell immunotherapies hold great promise for cancer treatment, but they are not very effective against solid tumors. Niki Spahich from The Scientist’s Creative Services team spoke with Katie McKenna, postdoctoral fellow in the laboratory of Malcolm Brenner at the Center for Cell and Gene Therapy at Baylor College of Medicine, about her work developing a combination CAR T cell immunotherapy and oncolytic virotherapy to treat solid tumors.

LabTalk is a special edition podcast produced by The Scientist’s Creative Services Team, where we explore topics at the leading edge of innovative research. This episode was sponsored by IsoPlexis.